Cognition Therapeutics downgraded by Cantor Fitzgerald
$CGTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Cantor Fitzgerald downgraded Cognition Therapeutics from Overweight to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/19/2024 | $1.00 → $1.50 | Neutral → Buy | B. Riley Securities |
| 7/30/2024 | Overweight → Neutral | Cantor Fitzgerald | |
| 11/3/2021 | $27.00 | Buy | B. Riley Securities |
| 11/3/2021 | $22.00 | Outperform | Oppenheimer |
Dr. James Galvin of the University of Miami to Serve as Lead Investigator First Site Initiated: Banner Sun Health Research Institute PURCHASE, N.Y., June 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced today it has received an anonymous philanthropic donation to substantially fund an expanded access program (EAP) for people with dementia with Lewy bodies (DLB). The generous donation comes from the family of a DLB patient who was treated with zervimesine in the Phase 2 SHIMMER study. Through this open-label EAP, participants will be provide
PURCHASE, N.Y., May 09, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical data this week at the Association for Research in Vision and Ophthalmology (ARVO) showing the potential for zervimesine (CT1812) to protect retinal pigment epithelial (RPE) cells from damage in dry age-related macular degeneration (dry AMD). "Dry AMD is driven by a number of factors that contribute to the death of retinal cells, leading to irreversible vision loss," stated Mary Hamby, PhD, vice president of research. "Preclinical research presented at ARVO supports our understanding of zervime
Zervimesine treatment slowed the rate of GA lesion growth by 28.6% compared to placebo Observed GA lesion area was reduced by 28.2% at 18 months compared to placebo Dry AMD results validate zervimesine's potential across degenerative disease indications PURCHASE, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported topline results today from the Phase 2 COG2201 ‘MAGNIFY' trial of zervimesine (CT1812) in adults with geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD). The results show zervimesine-treated participants had 28.6% slower GA
4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)
4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)
8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)
8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)
8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)
4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)
4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)
4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)
B. Riley Securities upgraded Cognition Therapeutics from Neutral to Buy and set a new price target of $1.50 from $1.00 previously
Cantor Fitzgerald downgraded Cognition Therapeutics from Overweight to Neutral
B. Riley Securities initiated coverage of Cognition Therapeutics with a rating of Buy and set a new price target of $27.00